2001 Cannabinoids Clinical Trials Terpenes 
The Cannigma
JANUARY 13, 2023
Based on the limited existing evidence, the best cannabis strain for migraines may be a Type II that includes both THC and CBD, and a terpene profile that includes beta-caryophyllene, myrcene, linalool, limonene, bisabolol, humulene or pinene. The study called out pinene, myrcene, and beta-caryophyllene as specifically useful terpenes.
CannaTech
SEPTEMBER 16, 2018
Canada has been at the forefront of shaping much of the rhetoric surrounding cannabis since 2001. Over time extended clinical trials will continue to map out the plant’s therapeutic effects, supporting it as an alternative medicine offering relief for a long list of conditions. Changing Cannabis Conversations Worldwide.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Cannabis Law Report
JULY 12, 2019
International Cannabinoid Cancer Research Institute (Draft 5). This paper seeks to answer why refined cannabinoids have more side effects than the natural cannabis product, as well as the possible etiology of said adverse reactions. Also discussed are other attempts at affecting the cannabinoid system from a singular standpoint.
Cannabis Law Report
JUNE 4, 2021
Rick, and MAPS, have published hundreds of research papers, articles, and reports over the past several decades in addition to participation in dozens of clinical trials and international studies. Rick Doblin, Ph.D, in/rickdoblin/ [link]. A THC version is expected to follow, and potentially one with psychedelic mushrooms.
Cannabis Law Report
NOVEMBER 24, 2021
The recreational use of cannabis is well known and attributed to its power as a psychotropic plant, specifically due to the cannabinoid tetrahydrocannabinol (THC). Only one article appeared in the MJA in 2000 and again in 2001. years (Atakan 2012 ). There was one case study and one book review during this period. Discussion.
Expert insights. Personalized for you.
132 
Let's personalize your content